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The Hypertensive Heart
An Integrated Understanding Informed by Imaging
Subha V. Raman, MD, MSEE
Columbus, Ohio
Clinical sequelae of hypertension include heart failure, arrhythmias, and ischemic events, especially myocardial
infarction and stroke. Recognizing the hypertensive heart has diagnostic as well as prognostic implications. Cur-
rent imaging techniques offer noninvasive approaches to detecting myocardial fibrosis, ischemia, hypertrophy,
and disordered metabolism that form the substrate for hypertensive heart disease. In addition, recognition of
aortopathy and atrial myopathy as contributors to myocardial disease warrant incorporation of aortic and atrial
functional measurements into a comprehensive understanding of the hypertensive heart. (J Am Coll Cardiol
2010;55:91–6) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.059S
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Rnvestigators of hypertensive heart disease (HHD) have
raditionally studied elements of its pathophysiology from
istinct perspectives—hypertrophy, hemodynamic models,
enetic influences, and neurohormonal pathways, to name a
ew. One is reminded of the allegory of the blind men who
alk into a forest and encounter an elephant, an animal
nknown to them. Each unseeing man tries to understand
hat stands before him by exploring what is closest—the
an feeling the stout leg labels it a tree, and another brushes
y the tail and thinks it is a rope. Ultimately, none “see” the
lephant for what it is without composing these disparate
erspectives into one. Such an aggregation of viewpoints is
imilarly required to better diagnose and treat HHD.
The ongoing need for coherence in comprehension is
vident when one finds that hypertensive patients’ risk of
eart failure has changed little since its recognition by large
opulation-based studies over the past decades (1). Also
pparent is the link between HHD and atrial fibrillation,
hose likelihood increases by 40% to 50% in the presence of
ypertension (2). Ventricular arrhythmias occur more fre-
uently in hypertensive patients (3), with QT dispersion
ncreasing directly with left ventricular (LV) mass (4).
ncreased susceptibility to ischemic heart disease rounds out
he cardiovascular sequelae of HHD, with a 6-fold higher
isk of myocardial infarction in hypertensive patients than in
ormotensive individuals (1).
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ccepted July 20, 2009.tructural Remodeling
ardiomyocyte hypertrophy is but one of many structural
lterations in HHD (5). Fibroblasts undergo hyperplasia
nd conversion to myofibroblasts, along with hypertrophy of
ascular smooth muscle cells. Noncellular elements central
o myocardial remodeling in HHD include expansion of
nterstitial and perivascular collagen that make up the
xtracellular matrix. Changes in intramyocardial capillary
ensity and arteriolar thickening compound ischemia in the
earts of patients with hypertension. These remodeling
vents are orchestrated via effects of biomechanical stress on
he extracellular matrix that, in turn, signals stretch-
ctivated ion channels leading to intracellular transmission
f signals to the nucleus, up-regulating hypertrophic gene
xpression. Similar transduction occurs from cytokine sig-
aling via intracellular calcium handling to myocardial
ransformation (6).
Is there a benefit to myocardial hypertrophy? In the
hort-term, increasing wall thickness in proportion to in-
reased pressure helps to normalize myocardial stress; he-
odynamic studies have shown that the pressure-
verloaded LV has reduced wall stress when compared with
he volume-overloaded ventricle (7). However, long-term
utcomes clearly worsen with progressive hypertrophy, with
ncreasing LV mass index translating to commensurate
ncreases in adverse cardiovascular events and all-cause
ortality (8). Conversely, regression of hypertrophy by
ither electrocardiographic measures or echocardiography
onfers lower rates of cardiovascular death, myocardial
nfarction, stroke, and all-cause mortality (9–11).
This underscores the need to measure LV mass with care,
s it informs not only diagnosis but also prognosis in HHD.
eliance on the electrocardiogram alone has limitations in
oth sensitivity and specificity of voltage-based criteria, an
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The Hypertensive Heart January 12, 2010:91–6understanding made possible with
the advent of cardiac imaging (12).
Particularly prone to error is the
diagnosis of LV hypertrophy in
young male patients using conven-
tional electrocardiographic criteria
(13). Echocardiography performs
well in detection of concentric
hypertrophy given an adequate
acoustic window; asymmetric and
milder forms of hypertrophy may
benefit from alternate imaging ap-
proaches. Reproducibility of LV
mass measurement using cardiac
agnetic resonance (CMR) is well-established (14), making it
he standard when evaluating newer techniques such as
-dimensional echocardiography (15). Cardiac computed to-
ography also allows precise measurement of LV mass
16,17), requiring less radiation exposure with progressive
echnological advances. High reproducibility is relevant to
linical practice as it affords the following: 1) cost-effective
ample size design in clinical trials of therapeutics targeting LV
ypertrophy; 2) quantitative investigation of rare diseases; and
) precise detection of serial changes in individual patients.
Figure 1 Magnetic Resonance T1 Mapping for Myocardial Fibro
(A) Images obtained at multiple inversion times show recovery of myocardial signa
shows an exponential recovery curve from which myocardial T1 can be calculated.
hancement, underscoring the need for more quantitative approaches. Reproduced
Abbreviations
and Acronyms
CMR  cardiac magnetic
resonance
HHD  hypertensive heart
disease
LGE  late gadolinium
enhancement
LV  left ventricle/
ventricular
31P-MRS  phosphorus
magnetic resonance
spectroscopyyocardial Fibrosis
common end point of many cellular and noncellular
athologic processes in HHD is myocardial fibrosis. Fibro-
is quantification in endomyocardial samples obtained via
ransjugular biopsy showed significantly greater collagen
olume fraction in patients with hypertension than in
ormotensive controls (18). Various imaging techniques
ave emerged to quantify myocardial fibrosis noninvasively.
chocardiography with integrated backscatter show good
orrelation with collagen volume fraction, recognizing that
lightly less than half of patients may have suitable back-
catter signal for analysis (19). A more robust approach for
isualization of myocardial fibrosis is late gadolinium en-
ancement (LGE)-CMR. This technique shows enhance-
ent in regions of fibrosis with appropriate T1-weighted
echniques 10 to 15 min after intravenous administration of
adolinium-based contrast because of: 1) expanded ex-
ravascular volume in fibrotic myocardium that is occupied
y this extracellular contrast agent; and 2) impaired efflux of
adolinium-based contrast due to vascular changes in fi-
rotic myocardium. A recent European study showed that
pproximately one-half of patients with LV hypertrophy
ue to arterial hypertension manifested patchy enhancement
uantification
initial inversion. (B) Plot of myocardial signal intensity versus inversion time (Tl)
nventional late post-gadolinium image shows minimal grossly apparent hyperen-
permission, from Iles et al. (23).sis Q
l after
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January 12, 2010:91–6 The Hypertensive Heartn LGE imaging (20); this pattern is clearly distinguishable
rom the subendocardial enhancement of infarcted myocar-
ium. Our group has shown that severity of diastolic
ysfunction increases with extent of fibrosis by LGE (21).
his suggests a potential noninvasive metric for trials of
ovel agents to treat heart failure with preserved ejection
raction, an all too common outcome in hypertensive
atients with diastolic dysfunction.
In other populations with cardiomyopathy, myocardial
nhancement by LGE-CMR has been shown to identify
ubstrate for ventricular arrhythmias and sudden cardiac
eath (22,23). Similar prospective studies in patients with
ypertrophy due to hypertension are needed before ascrib-
ng arrhythmia risk to the patchy enhancement seen in
HD.
Visibly enhanced myocardial regions by LGE-CMR may
e absent in HHD even in the presence of diffuse interstitial
brosis. This has prompted the development of T1 map-
ing. This technique may be applied to the entire myocar-
ium allowing quantification of differences in T1 relaxation,
n intrinsic property of spins or protons in fibrotic versus
ormal myocardium. These differences are further exagger-
ted after gadolinium administration, which showed good
orrelation with collagen volume fraction in a small study of
ost-orthotopic heart transplant patients (Fig. 1) (24). Brilla
t al. (25) used endomyocardial biopsy in patients with
ypertension and diastolic dysfunction to show that treat-
ent with an angiotensin-converting enzyme inhibitor
roduced measurable reduction in collagen volume fraction
Figure 2 Aortic Distensibility and Diastolic HF
(A) Aortic distensibility obtained with cine cardiac magnetic resonance imaging as
reduced in diastolic heart failure patients. (B) Peak oxygen consumption declines
with permission, from Hundley et al. (32). HF  heart failure; VO  oxygen consu2nd improved diastolic function, neither of which were
chieved with diuretic therapy despite similar improvement
n blood pressure control. One could envision similar studies
sing T1 mapping as an end point in future therapeutic trials
argeting fibrosis in HHD, eliminating the need for serial
nvasive myocardial sampling.
ascular and Other Changes
n Hypertensive Myocardial Disease
icrovascular disease and endothelial dysfunction are ap-
arent in hypertensive heart disease. A study of African-
merican men with hypertension showed progressive im-
airment of flow-mediated vasodilation as LV mass
ncreased (26), consistent with the previously described
ltrastructural remodeling of myocardial microvessels.
ooking directly at myocardial perfusion with vasodilator
tress CMR, Pilz et al. (27) showed increased frequency of
ypertension in patients with chest pain, angiographically
ormal coronary arteries, and subendocardial ischemia on
erfusion imaging. Of course, hypertensive patients may
lso have myocardial ischemia due to epicardial coronary
tenosis that can be detected noninvasively using stress
erfusion scintigraphy (28) or coronary computed tomog-
aphy (29).
At the macrovascular level, increased arterial stiffness
ften seen in long-standing hypertension accelerates aortic
ulse wave velocity (30). This, in turn, results in earlier
eturn of the wave reflected at the iliac bifurcation in systole,
roceeds from healthy young to healthy old individuals; distensibility is most
ge and is lowest in patients with diastolic heart failure. Adapted and reproduced,
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The Hypertensive Heart January 12, 2010:91–6ncreasing LV afterload and central pulse pressure. The
oncomitant fall in central diastolic blood pressure decreases
oronary perfusion, further contributing to myocardial isch-
mia. The pulse wave velocity measurement, either with
MR velocity-encoded imaging or multistation arterial
onometry, provides an assessment of aortic function. Ahi-
astos et al. (31) applied the latter in showing that
ngiotensin-converting enzyme inhibition affected its ben-
fit on aortic remodeling via lowering of aortic pulse wave
elocity, further mediated by changes in matrix metallopro-
einases and transforming growth factor-beta that are
nown to degrade aortic integrity (31). Aortic distensibility,
lbeit a load-dependent measure of aortic function, can be
eadily quantified using high temporal resolution cine CMR
echniques. With this approach, Hundley et al. (32) showed
progressive decline in aortic distensibility with age that
as lower still in patients with diastolic heart failure. These
ortic changes paralleled reduction in peak oxygen con-
Figure 3 The Many Aspects of Hypertensive Heart Disease
Hypertensive heart disease involves disparate elements, ranging from aortopathy
interact to produce sequelae such as heart failure, arrhythmias, and ischemic eveumption, an important metric of functional capacity that
urther illuminates how the aorta contributes to clinical
equelae of hypertension (Fig. 2).
Several other mechanisms warrant consideration in com-
leting our current understanding of hypertension and the
eart. Altered myocardial energy use in HHD has been
tudied by Lamb et al. (33) using phosphorus magnetic
esonance spectroscopy (31P-MRS) during pharmacologic
tress. Because of the critical role of adenosine triphosphate
nd creatine cycling in supplying myocytes with the energy
eeded for normal function, changes in the ratio of phos-
hocreatine to adenosine triphosphate that can be measured
oninvasively with 31P-MRS allow noninvasive quantification
f myocardial metabolism. With prolonged dobutamine and
tropine infusion to allow sufficient time to collect the
1P-MRS signal, patients with hypertension had measur-
bly lower phosphocreatine to adenosine triphosphate ratios
uring stress compared with healthy controls, indicating
cardial remodeling and even peripheral energy utilization that
gure illustration by Rob Flewell. LA  left atrium; LV  left ventricle.to myo
nts. Fi
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January 12, 2010:91–6 The Hypertensive Heartmpaired myocardial energetics. Recognizing the systemic
asculature’s role in energy use and blood flow may require
onsideration of not only myocardium but also skeletal
uscle in HHD, facilitated by imaging techniques such as
1P-MRS (34) and positron emission tomography with
5-oxygen labeled water (35).
Finally, no discussion of hypertensive heart disease would
e complete without appreciating the role of the left atrium.
s witness to chronically elevated LV filling pressures, left
trial enlargement is a reliable marker of diastolic dysfunc-
ion in the absence of mitral valve disease. The correlation
etween left atrial volume and brain natriuretic peptide
evels further underscores its role as sentinel in heart failure
ith preserved ejection fraction (36). Beyond passive expan-
ion, Kurt et al. (37) have recently shown that changes in
ctive left atrial strain by tissue Doppler may distinguish
etween asymptomatic patients with diastolic dysfunction
nd those with diastolic heart failure, something not feasible
ith traditional echo-Doppler measures such as E/E= ratio.
hus, left atrial myopathy warrants inclusion in our coales-
ent understanding of hypertensive heart disease.
uture Directions
ncreasing recognition of genetic factors that produce vari-
ble therapeutic response among patients with hypertension
38,39) should motivate better understanding of the struc-
ural and functional differences that mediate this heteroge-
eity. Imaging attuned to the multiple aspects of HHD
Fig. 3), by quantifying the degree to which specific ele-
ents predict variability in disease development and pro-
ression, can provide specific phenotypic evidence to guide
evelopment of novel therapeutics.
onclusions
he clinical burden of HHD is great, as is the opportunity
o develop new treatment options for patients with heart
ailure with preserved ejection function that so often results
rom unchecked hypertension. Innovation will require in-
estigations that consider hypertrophy, fibrosis, ischemia,
ltered metabolism, aortopathy, and atrial myopathy as
nterconnected mechanisms along the HHD spectrum.
ontemporary noninvasive imaging facilitates such an un-
erstanding, and warrants incorporation into pre-clinical
esearch and therapeutic trials to improve the lives of
atients with HHD.
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